{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-193351","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.644116+00:00","generated_at":"2026-05-17T08:59:34.418395+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zymeworks discontinues ZW171 Phase 1 after dose escalation; benefit-risk profile unfavorable","bullets":["Decision based on completed dose escalation in ovarian and NSCLC patients; MTD established but benefit-risk not supportive.","Dose-limiting toxicities consistent with mesothelin-related on-target off-tumor toxicity; CRS was well-managed.","Ongoing participants may continue at investigator discretion; discontinued patients remain in safety follow-up.","Pipeline continues: ZW191 Phase 1 ongoing, ZW251 Phase 1 expected 2025, ZW209 IND filing planned H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-193351","json":"https://secwatch.observer/filing/0001193125-25-193351.json","markdown":"https://secwatch.observer/filing/0001193125-25-193351.md","text":"https://secwatch.observer/filing/0001193125-25-193351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312525193351/0001193125-25-193351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312525193351/d88452d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:59:34.418395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}